Strategic transaction
Search documents
Prismo Metals Closes Strategic Transaction with Blade Resources
Thenewswire· 2026-03-05 23:40
Core Viewpoint - Prismo Metals Inc. has successfully completed a transaction with Blade Resources Inc., transferring its rights in the Hot Breccia copper project to Blade, while retaining a significant stake in Blade [1][10][12]. Transaction Details - Prismo received 6,755,000 common shares of Blade and a cash payment of $185,000, making it the largest single shareholder with approximately 24% ownership [10][12]. - The transaction is expected to enhance Prismo's access to capital for the Hot Breccia drill program without diluting its shareholders [12][17]. Drilling Update at Silver King - The first drill hole at the Silver King project reached a depth of 477 feet (145 meters) and successfully intersected mineralized zones, confirming the presence of silver minerals [3][5]. - The current drilling program is fully funded and aims to test the upper portion of the mineralized body, with an initial estimate of 1,000 meters of diamond drilling planned [3][5]. - The second drill hole is currently at a depth of 155 feet, with further drilling anticipated to explore deeper levels and adjacent areas [3][5]. Geological Context - The Silver King and Magma Mines share a similar geological framework, with Silver King featuring silver-dominant veins and potential for deeper copper mineralization [6][5]. - The mineralization at Silver King is characterized by epithermal-mesothermal silver veins, contrasting with Magma's copper-focused deposits, indicating potential for polymetallic extensions [6][5]. Strategic Focus - The company will concentrate on advancing its remaining projects in Arizona, specifically Silver King and Ripsey Gold, while Blade focuses on the Hot Breccia project [17]. - Prismo has the right to nominate a representative to Blade's board and has participation rights in future equity offerings to maintain its ownership percentage [17][12].
Mobix Labs and Peraso Engage in Further Discussions Regarding a Potential Strategic Transaction
Globenewswire· 2026-01-21 12:00
Core Viewpoint - Mobix Labs is in discussions with Peraso regarding a potential strategic transaction, which may involve an all-stock deal at a premium to Peraso's trading price, although no agreement has been reached yet [1][3][2] Group 1: Company Overview - Mobix Labs, Inc. is a fabless semiconductor and connectivity company focused on defense, aerospace, and high-reliability applications, offering RF, interconnect, and related solutions [5] - Peraso, Inc. specializes in high-performance 60 GHz unlicensed and 5G mmWave wireless technology, providing chipsets, modules, software, and IP for various applications including military and factory automation [6] Group 2: Strategic Rationale - The CEO of Mobix Labs emphasized the strategic opportunity presented by Peraso's wireless capabilities, which are complementary to Mobix Labs' offerings, potentially accelerating the company's strategy in mission-critical markets [4]
Harmonic Announces Pending Sale of Its Video Business to MediaKind
Prnewswire· 2025-12-08 12:35
Core Viewpoint - Harmonic has received a binding offer from MediaKind to acquire its Video Business segment for approximately $145 million in cash, which is expected to close in the first half of 2026, subject to regulatory approvals and employee consultation processes [1][2][3] Group 1: Transaction Details - The proposed acquisition is valued at around $145 million in cash [1][7] - The transaction is anticipated to close in the first half of 2026, pending regulatory approvals and a consultation process with the French employee works council [1][2] - Harmonic's Video Business will be integrated into MediaKind, which aims to enhance its product solutions and innovation capabilities [3][7] Group 2: Strategic Implications - This divestiture will allow Harmonic to sharpen its focus on its core Broadband business and growth priorities [2][3] - The transaction is expected to provide a significant capital infusion, improving Harmonic's balance sheet and financial flexibility [2][3] - MediaKind's acquisition of Harmonic's Video Business is seen as a strategic move to strengthen its position in the video delivery market and enhance its research and development capabilities [3][7] Group 3: Company Background - Harmonic is recognized as a leader in virtualized broadband and video delivery solutions, enabling high-quality video streaming and broadcast services globally [6][8] - MediaKind is a prominent player in the video technology landscape, serving over 2,000 global service providers and content owners [9]
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Globenewswire· 2025-12-01 12:00
Core Insights - KALA BIO, Inc. has entered into a $6 million securities purchase agreement with private investor David E. Lazar for non-voting convertible preferred stock, with an initial investment of $1.8 million received [1][3] - Following the investment, David E. Lazar has been appointed as the new Chief Executive Officer and Chairman of the Board, while former CEO Todd Bazemore remains on the Board [1][3] - KALA plans to continue the evaluation and redevelopment of its product candidates, particularly KPI-012, despite previous setbacks in clinical trials [2][3] Investment and Financials - The investment agreement includes a second closing contingent on stockholder approval, which is expected in the first quarter of 2026, involving an additional $4.2 million investment [3] - KALA has issued new shares of non-voting convertible Series AA preferred stock in exchange for the initial investment [3] Clinical Development - KALA's KPI-012 did not meet the primary endpoint in its Phase 2b clinical trial for treating persistent corneal epithelial defect, leading to a temporary halt in its development [2] - The company aims to explore strategic options and continue evaluating its therapeutic candidates for potential standalone uses or in combination with other products [2] Company Overview - KALA BIO, Inc. focuses on innovative therapies for rare and severe eye diseases, utilizing its proprietary mesenchymal stem cell secretome platform [4] - KPI-012 has received Orphan Drug and Fast Track designations from the FDA for treating persistent corneal epithelial defect [4]